Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Clinical response: no clinically significant response in mental state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Service outcomes: Hospitalisation · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: Spinal fracture (short‐term) · patients with schizophrenia
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY may leads to lower adverse effects: Spinal fracture (short‐term) compared with ELECTROCONVULSIVE THERAPY (low certainty).
1 finding from 1 review
Quality of life: No clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review